Efalizumab-induced hypertrichosis

British Journal of Dermatology

Volumn 158, Issue 5, 2008, Pages 1158-1159

  Rallis, E ^a   Tapinis, P ^a   Verros, C D ^b  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b NONE

Author keywords

Adverse reaction; Efalizumab; Hypertrichosis

Indexed keywords

CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; METHOTREXATE; TESTOSTERONE;

AGED; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTRICHOSIS; LETTER; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; HYPERTRICHOSIS; IMMUNOLOGIC FACTORS; PSORIASIS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 42049087206     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08511.x     Document Type: Letter

References (4)

1. Dubertret L, Sterry W, Bos JD et al. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 155 : 170 81.
2. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006 5 : 197 209.
3. Wendelin DS, Pope DN, Mallory SB. Hypertrichosis. J Am Acad Dermatol 2003 48 : 161 79.
4. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev 2001 81 : 449 94.